Sigma-Aldrich Enters RNAi Market, But Leaves Blank its Cost to Get in | GenomeWeb

Sigma-Aldrich last week moved to enhance its oligonucleotide portfolio — specifically its RNA interference reagent position — by entering into a definitive agreement to acquire Boulder, Colo.-based Proligo.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.